SEARCH

SEARCH BY CITATION

References

  • 1
    Tarui T, Majumdar M, Miles LA, Ruf W, Takada Y. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. J Biol Chem 2002; 277: 56470.
  • 2
    Liotta LA. Cancer cell invasion and metastasis. Sci Am 1992; 266 (549): 623.
  • 3
    Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 2003; 54: 37189.
  • 4
    Biswas C, Zhang Y, DeCastro R et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 4349.
  • 5
    Yan L, Zucker S, Toole BP. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 2005; 93: 199204.
  • 6
    Chen ZN, Liu YF. Monoclonal antibody HAb18 to human hepatoma. Monoclonal Antibodies 1990; 8: 11.
  • 7
    Liu YF, Chen ZN, Ji YY. Localization of hepatocellular carcinoma with monoclonal antibodies. Zhonghua Yi Xue Za Zhi 1991; 71: 3625.
  • 8
    Chen ZN, Xing JL, Zhang SH, inventors; NTD Patent & Trademark Agency. Beijing office, assignee. Anti-human hepatoma monoclonal antibody HAb18 light/heavy chain variable region gene, and use thereof. Chinese patent ZL02114471.0, 2002 March 15; PCT international patent WO03/078469; 2003 March 17.
  • 9
    Chen ZN, Shang P, Li Y, Qian AR, Zhu P, Xing JL, inventors; NTD Patent & Trademark Agency. Beijing office, assignee. HAb18G/CD147, its agonist and application. Chinese patent ZL01131735.3, 2001 Sep 28; PCT international patent WO02/094875; 2002 May 27.
  • 10
    Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN, Chan HC. The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem 2001; 276: 8707.
  • 11
    Jiang JL, Chan HC, Zhou Q et al. HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains. Cell Mol Life Sci 2004; 61: 208391.
  • 12
    Chen ZN, Mi L, Xu J et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006; 65: 43544.
  • 13
    Xu J, Xu HY, Zhang Q et al. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res 2007; 5: 60514.
  • 14
    Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 16195.
  • 15
    Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999; 340 (Pt 1): 7784.
  • 16
    Brownstein C, Deora AB, Jacovina AT et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 2004; 103: 31724.
  • 17
    Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 2006; 81: 14656.
  • 18
    Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 2007; 13: 356875.
  • 19
    Hayes MJ, Shao D, Bailly M, Moss SE. Regulation of actin dynamics by annexin 2. EMBO J 2006; 25: 181626.
  • 20
    Hayes MJ, Merrifield CJ, Shao D et al. Annexin 2 binding to phosphatidylinositol 4,5-bisphosphate on endocytic vesicles is regulated by the stress response pathway. J Biol Chem 2004; 279 (14): 15764.
  • 21
    Singh P. Role of Annexin-II in GI cancers: interaction with gastrins/progastrins. Cancer Lett 2007; 252: 1935.
  • 22
    Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008; 216: 13140.
  • 23
    Liu JW, Shen JJ, Tanzillo-Swarts A et al. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003; 22: 147585.
  • 24
    Hastie C, Masters JR, Moss SE, Naaby-Hansen S. Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells. J Biol Chem 2008; 283: 595603.
  • 25
    Lou CY, Feng YM, Qian AR et al. Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98. World J Gastroenterol 2004; 10: 14625.
  • 26
    Li Y, Tang ZY, Ye SL et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 2001; 7: 6306.
  • 27
    Suzuki S, Sato M, Senoo H, Ishikawa K. Direct cell–cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp Cell Res 2004; 293: 25966.
  • 28
    Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002; 99: 5208.
  • 29
    Bordador LC, Li X, Toole B et al. Expression of emmprin by oral squamous cell carcinoma. Int J Cancer 2000; 85: 34752.
  • 30
    Jiang JL, Tang J. CD147 and its interacting proteins in cellular functions. Sheng Li Xue Bao 2007; 59: 51723.
  • 31
    Xu HY, Qian AR, Shang P et al. siRNA targeted against HAb18G/CD147 inhibits MMP-2 secretion, actin and FAK expression in hepatocellular carcinoma cell line via ERK1/2 pathway. Cancer Lett 2007; 247: 33644.
  • 32
    Tang J, Wu YM, Zhao P, Yang XM, Jiang JL, Chen ZN. Overexpression of HAb18G/CD147 promotes invasion and metastasis via alpha3beta1 integrin mediated FAK-paxillin and FAK-PI3K-Ca(2+) pathways. Cell Mol Life Sci 2008; 65: 293342.
  • 33
    Qian AR, Zhang W, Cao JP et al. Downregulation of CD147 expression alters cytoskeleton architecture and inhibits gelatinase production and SAPK pathway in human hepatocellular carcinoma cells. J Exp Clin Cancer Res 2008; 27: 50.
  • 34
    Rescher U, Ruhe D, Ludwig C, Zobiack N, Gerke V. Annexin 2 is a phosphatidylinositol (4,5)-bisphosphate binding protein recruited to actin assembly sites at cellular membranes. J Cell Sci 2004; 117: 347380.
  • 35
    Merrifield CJ, Rescher U, Almers W et al. Annexin 2 has an essential role in actin-based macropinocytic rocketing. Curr Biol 2001; 11: 113641.
  • 36
    Zobiack N, Rescher U, Laarmann S, Michgehl S, Schmidt MA, Gerke V. Cell-surface attachment of pedestal-forming enteropathogenic E. coli induces a clustering of raft components and a recruitment of annexin 2. J Cell Sci 2002; 115: 918.
  • 37
    Royal I, Park M. Hepatocyte growth factor-induced scatter of Madin–Darby canine kidney cells requires phosphatidylinositol 3-kinase. J Biol Chem 1995; 270: 7807.
  • 38
    Curtin KD, Meinertzhagen IA, Wyman RJ. Basigin (EMMPRIN/CD147) interacts with integrin to affect cellular architecture. J Cell Sci 2005; 118: 264960.
  • 39
    MacLeod TJ, Kwon M, Filipenko NR, Waisman DM. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem 2003; 278: 57784.
  • 40
    Waisman DM. Annexin II tetramer: structure and function. Mol Cell Biochem 1995; 149-150: 30122.
  • 41
    Carmeliet P, Moons L, Lijnen R et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 43944.
  • 42
    McColl BK, Baldwin ME, Roufail S et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med 2003; 198: 8638.